Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Investig Dermatol Symp Proc ; 12(1): 48-9, 2007 May.
Article in English | MEDLINE | ID: mdl-17502870

ABSTRACT

Etanercept (Amgen Inc, Thousand Oaks, CA) is a human soluble p75 tumor necrosis factor (TNF) receptor-human-IgG1 (hup75 TNFR-huIgG1) fusion protein used in the treatment of chronic inflammatory diseases in humans, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. To be able to study the effects of the soluble receptor fusion protein in mouse models, including those that mimic human granulomatous infections, a murine soluble p75-TNF receptor-murine IgG1 (murine p75-murine IgG1) fusion protein had to be constructed. This article discusses the generation, large-scale production, and purification of this molecule.


Subject(s)
Immunoglobulin G/biosynthesis , Immunoglobulin G/isolation & purification , Receptors, Tumor Necrosis Factor/biosynthesis , Receptors, Tumor Necrosis Factor/isolation & purification , Animals , Etanercept , Humans , Mice , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/isolation & purification , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL